BRAF and melanoma: Furthermore, the pharmacological inhibition or knockdown of YAP in BRAF inhibitor resistant melanoma cells decreased ERK1/2 signaling, remodeling of the actin cytoskeleton and tumor growth and therefore enhanced BRAF inhibitor efficacy (14, 66).